At the news
? BULLISHIMPACT 8/10 8-K filed Apr 23, 2026 at 16:20 ET
Edwards Lifesciences reported strong Q1 2026 results with sales up 16.7% to $1.65B and adjusted EPS of $0.78, beating consensus by $0.05. The company raised full-year 2026 guidance for sales growth to 9-11% (from 8-10%) and adjusted EPS to $2.95-$3.05 (from $2.90-$3.05), citing strong TAVR and TMTT momentum and clinical catalysts.
- Q1 sales grew 16.7% YoY to $1.65B, constant currency growth of 12.7%
- Q1 adjusted EPS was $0.78, beating consensus of $0.73
- Raised full-year 2026 constant currency sales growth guidance to 9-11% (from 8-10%)
- Raised full-year 2026 adjusted EPS guidance midpoint to $2.95-$3.05 (from $2.90-$3.05)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access